.png)
Large Pharmaceutical
HTA, Value & Evidence, Global Access Strategy & Pricing
Phase III
Dermatology
Subscribe to our newsletter to receive the latest case studies.
Large Pharmaceutical
HTA, Value & Evidence, Global Access Strategy & Pricing
Phase III
Dermatology
The client was developing a systemic therapy with Phase III trials underway.
Payers were expected to question whether the condition represented a true medical need, creating a challenging access and pricing environment.
The client engaged Alkemi to identify effective ways to convey unmet need, demonstrate value, and inform U.S. market access and pricing strategy.
1. Conducted secondary research to assess the disease landscape and identify relevant analogues to inform payer discussion.
2. Designed payer advisory materials, including value narratives, clinical logic, and discussion guides structured to elicit decision-relevant feedback.
3. Moderated a payer advisory board with U.S. payers, KOLs, and clinical experts to test assumptions and capture insights on access and pricing expectations.
Use payer input early to shape strategy rather than react to it later.
"Thanks to the whole team involved in staging this Advisory Council. I was fortunate to be able to attend and here the insights from the council members firsthand. The report provides an excellent summary." - VP, Global Access Strategy and Pricing Lead
Payer feedback clarified how unmet need and value would be evaluated, reducing uncertainty around coverage and pricing.
Insights were used to refine how the therapy’s value was framed in payer discussions.
Early testing helped the client enter later-stage planning with greater confidence in access and pricing strategy.